RESUMO
Introduction. According to International Agency for Research on Cancer in 2040, about 3 million new cases of breast cancer (BC) are predicted and about 1 million women are expected to die from this pathology. The aim of the study to assess the impact of COVID-19 on the indicators of the oncological service for breast cancer in Kazakhstan. Material and research methods. The main method was a retrospective study using descriptive, analytical methods of biomedical statistics and data of the Ministry of Health of the Republic of Kazakhstan - form No.7 and 35 regarding BC (ICD 10 - C50) for 2011-2020. Results. For 2011-2020 42,376 new cases of BC and 12,914 deaths from this pathology were registered. The average annual crude incidence rate was 46.4+or-1.10/0000 (95%CI=44.3-48.5), and increased from 40.8+or-0.70/0000 (2011) to 51 .3+or-0.70/0000 in 2019 and then decrease to 44.2+or-0.70/0000 in 2020 (p<0.001). In dynamics, mortality rates tended to (p<0.001) decrease from 16.1+or-0.40/0000 (2009) to 11.9+or-0.40/0000 in 2019 and 11.5+or- 0.40/0000 in 2020, and the average annual crude mortality rate was 14.2+or-0.60/0000 (95%CI=13.1-15.3). Indicators of early diagnosis (stage I-II) improved from 73.4% (2011) to 86.9% in 2019, and decreased to 84.2% in 2020. Proportion of patients with stage III decreased (from 20.9% in 2011 to 8.4% in 2019 and to 10.0% in 2020) and stage IV (from 5.6% to 4.2% and 5.0%, respectively), i.e. neglect rates are declining. The indicators of morphological verification improved from 95.7% to 99.4% over the years. Conclusions. As a result of the analysis, an improvement in the indicators of morphological verification, early diagnosis, a decrease in the neglect and mortality rates were established. The trends in 2011-2019 differed significantly from the period from 2011-2020, which is due to the COVID-19 pandemic on the registration of BC.
RESUMO
BACKGROUND: A common secondary effect after SARS-CoV-2 immunization is an increased in size of the axillary lymph nodes ipsilateral to the vaccinated site. Eventually, an increased in size of the axillary lymph nodes may lead to a misinterpretation of the breast screening mammogram, performed in asymptomatic women between the age 50 to 69 years old for early breast cancer diagnosis. The aim of our research was to evaluate the impact of the vaccination for SARS-CoV-2 in the breast screening programmes in terms of recall rates and number of false positive results. As a secondary purpose we would analysed the protocols adopted by different breast screening units around the world after SARS-CoV-2 vaccination. METHODS: Observational and retrospective study analysing breast screening mammograms from a single Breast Cancer Screening Unit in Madrid. The mammograms of previously vaccinated women were analysed, reviewing the axillary lymph nodes and the re-call rate secondary to axillary lymphadenopathies. RESULTS: Four hundred and twenty three screening mammograms were performed in May 2021 in the University Hospital Ramon y Cajal in Madrid, which is part of the Breast Screening Programme in Madrid, Spain. None of the women previously vaccinated for SARS-CoV-2 were recalled for complementary studies due to an increased in the axillary lymph nodes. CONCLUSIONS: The protocol stablished by the Spanish Society of Breast Image that stands up for a routine breast screening mammogram after SARS-CoV-2 immunization, has no increase in the recall rate or increase in number of false positives.
RESUMO
State of the matterDue to the COVID-19 pandemic, and the resulting bottlenecks in the French healthcare system, the management of patients with COVID-19 has been prioritized over that of patients with other pathologies, in particular chronic diseases. The objective of this study was to investigate the impact of COVID-19 on the discovery stage of cancers diagnosed in an organized breast cancer screening program, as well as the impact on the time to supported. Material and methodsAll women aged 50 to 74 for whom cancer has been diagnosed in Cote d'Or as part of the national organized breast cancer screening program (first or second reading) from January 1, 2019 to December 31, 2020 have were included in this study. Using data from pathological anatomy laboratories, clinical centers, and the breast and gynecological cancer registry in Cote d'Or, France, we collected sociodemographic, clinical, and treatment data from all patients. We compared data from the year 2019 (pre-COVID) with that of the year 2020 (COVID). ResultsIn this study, we did not observe any change in the stage of discovery of the cancer at the time of diagnosis, nor any change in the therapeutic strategy. However, we observed a significant increase in infiltrated tumors, a decrease in in situ tumors, and the finding of larger clinical size of in situ tumors after the COVID pandemic. ConclusionWhile these results are reassuring, continued monitoring is needed to determine post-pandemic effects.
RESUMO
Background: COVID-19 pandemic brought pressure to Portuguese National Health Service (NHS). We aim to assess pandemic impact on diagnosis and management of breast cancer (BC) in a high-volume Portuguese comprehensive cancer centre, which was classified as a COVID-free institution by public health authorities.
RESUMO
Background: Cancer patients are more sensitive to infection induced by SARS-CoV-2, especially ones with impaired immune response. Vaccines are approved as safe and effective, and they are recommended in oncology patients. The aim of our study was to see the percentage of reinfections after second dose of vaccines against SARS-CoV2.
RESUMO
Background: The COVID-19 pandemic has led to more than 260 million infections and 55 million deaths as of early December 2021, worldwide. Vaccinating people against COVID-19 is considered as he best approach to overcome the pandemic since COVID 19-vaccines are effective and can reduce the risk of getting and spreading the virus. However, their efficacy and safety in patients with underlying disease such as cancers have not been approved yet. Here we report a cohort study on immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer, who were vaccinated as a part of a national plan for vaccination of patients with special diseases.
RESUMO
Background: COVID-19 has impacted every aspect of our lives. Flooding of hospitals with COVID-19 patients have affected quality of care given to breast cancer patients. Our aim is to assess the impact of COVID-19 on presenting cases of breast cancer and worsening of breast cancer stage and/or TNM classification.
RESUMO
Background: Breast cancer (BC) ranks first in the structure of cancer incidence among women in Kazakhstan. Mammography screening was implemented in 2008. Lockdowns and restrictive procedures with the full and partial cancellation of screening, took place in Kazakhstan in 2020-2021.
RESUMO
Background: The epidemic start of Coronavirus disease it expanded in the first months of 2020. Italy was among the first European countries to be affected and those affected more intensely: the first case was reported on 02.20.2020 The entire health system has been disrupted and reorganized due to the impact of the pandemic on hospitals The suspension of first-level screening services in Italy occurred in the months of March and April 2020 on throughout the national territory, starting from May 2020 the screening programs were reactivated albeit with different timing and intensity between the regions and within of each single region.
RESUMO
Background: COVID-19 pandemic motivated a reorganization of healthcare institutions, which may have led to a negative impact on cancer patients' treatment. This study compared the pathological response (PR) rate to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients who underwent treatment before (BCv) and during (DCv) the COVID-19 pandemic at our institution.
RESUMO
Objective: All equipment and personnel used in the healthcare field during the COVID-19 pandemic may need to be used for the isolation, diagnosis and treatment of pandemic patients. So we think that there may have been some delays in surgical treatment in the oncological patient group during the pandemic period. For this reason, we aimed to compare the demographic and clinicopathological characteristics of patients who were operated with the diagnosis of breast cancer before and during the pandemic in our center. Material and Method: The study was retrospectively designed at Eskisehir Osmangazi University Hospital General Surgery Clinic. Demographic and clinicopathological data of all patients who were operated for breast cancer 9 months before and 9 months after the declaration of the pandemic were retrospectively analyzed and compared statistically.
RESUMO
Background: Coronavirus disease 2019 (COVID-19) has spread rapidly across the globe through coughing, sneezing, droplet inhalation, and contact. Objectives: The current study aimed to assess the impact of the fear of COVID-19 infection on functionality in women with breast cancer.
RESUMO
Worldwide, the study shows that breast cancer is one of the major cancer responsible for women death. All the effective therapies - immune-modulator therapy, chemo-radiation and cell targeted therapies can worsen the body immune system which majorly affects the lungs and these women with weak immune system and bronchi problems are more susceptible to major complications if they are exposed to COVID-19. In start of pandemic, it was difficult for healthcare system to manage the surgeries, scans and therapies of cancer patients without let them exposed to SARCoV-2, leads to delay in their treatment which can even more worsen condition for the patient. SARCoV-2 triggers the IL-6 release by the formation of neutrophil extracellular trap which can increase the complications in the breast cancer patient as well as it can also reactivate the relapsed dormant breast cancer cells. So, after seeing the condition of patients doctors decided that they can treat the patients by taking all measuring safety precautions during the admission to the hospital and found Anti-IL-6 receptor (tocilizumab) neutrophils inhibitor (alvestat) and JAK1/JAK2 inhibitors (baricitinib) effective and vaccines are also available in international market considering them safe and efficient for patient with breast cancer history or maybe undergoing in treatment.
RESUMO
Context: COVID-19 pandemic has resulted in considerable overloading of health care systems in almost all regions of the world. Among different malignancies, breast cancer can be considered as a typical example of how the decision-making process for radiation treatment can be adapted to unusual situations. There exist several international guidelines in order to modify radiotherapy treatments during the COVID-19 pandemic, however, some of their recommendations are not applicable in regions with limited resources. In this manuscript, we provided guidance to deliver radiotherapy to patients with breast cancer during the COVID-19 pandemic based on our available nationwide resources. Evidence Acquisition: A team of expert radiation oncologists convened multidisciplinary and cross-institutional meetings and reviewed the major internationally published guidelines and relevant literature in the field of breast radiotherapy during the COVID-19 pandemic in order to establish recommendations for the safe application of radiation regimens based on the national limited resources.
RESUMO
These proceedings contain 25 papers from the 64th Annual Meeting of the Pathology Section of the German Veterinary Medical Association. Topics include tumour infiltrating lymphocytes in mammary carcinomas in domestic rabbits;what decides good or bad? - global gene expression analysis of the adenoma of the hepatoid perianal glands and adenocarcinoma the canine apocrine anal sac glands;the canine cutaneous histiocytoma - boring or perspective in immuno-oncology?;impact of antibiotic pretreatment on ventilator-induced lung injury: contradiction between histology and transcriptome analysis?;characterization of murine satellite glial cells of the dorsal root ganglia - a unique cell population with potential regenerative capacities;impact of antibiotic pretreatment on ventilator-induced lung injury: contradiction between histology and transcriptome analysis?;primary diffuse leptomeningeals oligodendrogliomatosis in a cat;pathomorphological studies of fibroadnexal dysplasia in dogs;pyogranulomatous inflammation in multiple Organs of a dog with evidence of Corynebacterium tuberculostearicum;ovary tumors in cats - overview of the examination material from 2009-2020 and case report of a recurrent dysgerminoma;atherosclerosis in the dog;spinal neuroenteric cyst in one Saint Bernard;MENX - an endogenous model for pseudohypoxic pheochromocytomas;molecular Level Evolution II: similarities of CLCA2 in sauropsids and mammals;in vivo detection of double-stranded Ribonucleic acid (RNA) as an early detection marker unclear viral infections using the example of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) in experimental infected hamsters;the role of different mast cell subtypes in the context of intestinal carcinogenesis - a species-comparative approach;an underestimated treasure in paraffin - establishment of a global transcriptome analysis canine tumors from FFPE material based on QuantSeq 3' technology;well researched? - an approximation of the role of CLCA1 in joints through usage molecular databases;integration of digitized historical and cytopathology into an open source DICOM database and viewer system;3R 3D: skin model for the study of viral infections;CARD9 signaling promotes hippocampal neurogenesis and cytokine balance in a mouse model of virus-induced encephalitis;neuropathological changes after intranasal infection with Rift Valley fever virus - a murine model for human encephalitis;a T-cell a day keeps Theiler away - the influence non-reactive T-cells on the course of a Theiler virus infection in mice with C57BL/6 background;digitization in pathology - new opportunities and their obstacles;and specific features of satellite glial cells of dog and pig.
RESUMO
Introduction and objective: Prophylactic examinations allow the reduction in morbidity from breast cancer and cervical cancer. The aim of the study was to estimate the impact of COVID-19 pandemic and the first months of restrictions in public life, introduced due to the risk of its outbreak, on the provision of services within cancer prevention programmes in Poland. Material and methods: The analysis was performed based on information concerning the number of mammography and cytology tests carried out as part of the breast cancer screening programme and cervical cancer screening programme. The study was conducted during January - May in 2020, and the same period in 2019 - as a basis for comparison. The data relate to three (out of sixteen) Polish Provinces: Katowice, Warsaw and Olsztyn.